EWTX · Edgewise Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $42.65M | - | $37.48M | $33.56M | $36.76M | - | $32.22M | $30.68M | $27.69M | - |
| SG&A | $11.46M | - | $9.38M | $9.05M | $9.20M | - | $8.21M | $7.43M | $7.06M | - |
| Total Operating Expenses | $54.12M | - | $46.86M | $42.61M | $45.96M | - | $40.43M | $38.11M | $34.75M | - |
| D&A | $537.0K | - | $500.0K | $500.0K | $513.0K | - | $500.0K | $500.0K | $473.0K | - |
| Operating Income | ($54.12M) | - | ($46.86M) | ($42.61M) | ($45.96M) | - | ($40.43M) | ($38.11M) | ($34.75M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($49.01M) | - | ($40.67M) | ($36.12M) | ($40.80M) | - | ($34.13M) | ($31.50M) | ($28.52M) | - |
| EPS - Basic | ($0.46) | - | ($0.39) | ($0.34) | ($0.43) | - | ($0.36) | ($0.34) | ($0.33) | - |
| EPS - Diluted | ($0.46) | - | ($0.39) | ($0.34) | ($0.43) | - | ($0.36) | ($0.34) | ($0.33) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.21M | $61.15M | $46.00M | $43.40M | $49.92M | $41.67M | $44.81M | $43.48M | $30.26M | $86.10M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.29M | $6.01M | $6.16M | $8.32M | $8.79M | $5.58M | $5.65M | $6.80M | $4.72M | $4.03M |
| Current Assets | $509.79M | $543.38M | $573.90M | $603.25M | $443.18M | $475.48M | $499.44M | $519.44M | $541.43M | $327.00M |
| Total Assets | $518.52M | $552.60M | $583.47M | $613.33M | $454.39M | $486.82M | $511.28M | $531.65M | $553.81M | $340.04M |
| Current Liabilities | $22.54M | $27.37M | $21.65M | $20.90M | $21.11M | $23.86M | $18.96M | $17.18M | $14.60M | $16.77M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $25.32M | $30.35M | $24.82M | $24.26M | $24.67M | $27.60M | $22.41M | $21.17M | $18.86M | $21.20M |
| Stockholders' Equity | $493.20M | $522.26M | $558.65M | $589.07M | $429.72M | $459.22M | $488.88M | $510.47M | $534.94M | $318.83M |
| Retained Earnings | ($595.38M) | ($546.37M) | ($496.15M) | ($455.49M) | ($419.37M) | ($378.58M) | ($338.91M) | ($304.79M) | ($273.29M) | ($244.76M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($42.54M) | - | - | - | ($37.87M) | - | - | - | ($28.60M) | - |
| Investing Cash Flow | $2.43M | - | - | - | $43.90M | - | - | - | ($268.31M) | - |
| Financing Cash Flow | $12.17M | - | - | - | $2.22M | - | - | - | $241.07M | - |
| CapEx | $44.0K | - | - | - | - | - | - | - | $297.0K | - |
| Free Cash Flow | ($42.59M) | - | - | - | - | - | - | - | ($28.89M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.87 | - | - | - | - | - | - | - | 1.01 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.5% | - | -7.0% | -5.9% | -9.0% | - | -6.7% | -5.9% | -5.2% | - |
| Return on equity | -9.9% | - | -7.3% | -6.1% | -9.5% | - | -7.0% | -6.2% | -5.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 22.61 | 19.85 | 26.51 | 28.87 | 20.99 | 19.93 | 26.35 | 30.24 | 37.08 | 19.50 |
| Quick ratio | 22.61 | 19.85 | 26.51 | 28.87 | 20.99 | 19.93 | 26.35 | 30.24 | 37.08 | 19.50 |
| Cash ratio | 1.47 | 2.23 | 2.13 | 2.08 | 2.36 | 1.75 | 2.36 | 2.53 | 2.07 | 5.13 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.05 | 1.06 | 1.04 | 1.04 | 1.06 | 1.06 | 1.05 | 1.04 | 1.04 | 1.07 |
| Liabilities / Assets | 0.05 | 0.05 | 0.04 | 0.04 | 0.05 | 0.06 | 0.04 | 0.04 | 0.03 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.8x | - | 3.1x | 2.3x | 4.9x | - | 5.1x | 3.3x | 3.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -17.7% | - | -15.9% | -11.8% | -32.2% | - | -37.3% | -50.4% | -35.2% | - |
| Net income growth (YoY) | -20.1% | - | -19.2% | -14.7% | -43.0% | - | -32.7% | -46.7% | -24.9% | - |
| EPS growth (YoY) | -7.0% | - | -8.3% | 0.0% | -30.3% | - | 12.2% | 0.0% | 8.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -6.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 14.8% | 13.7% | 14.3% | 15.4% | -19.7% | 44.0% | 68.3% | 63.9% | 62.7% | -8.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Edgewise Therapeutics against the 5 most active filers in the same SIC group.